Other metabolic diseases | Report Store | Pharma Intelligence

Market Spotlight: Amyloidosis

This Market Spotlight report covers the amyloidosis market, comprising key marketed and pipeline drugs, key upcoming events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.

July 31, 2020

Find out more

Non-alcoholic steatohepatitis (NASH) Market and Forecast Analysis to 2038

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of patients who have fatty liver in the absence of significant alcohol consumption. NAFLD patients are often segmented into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) patients.

May 22, 2020

Find out more

Market Spotlight: Duchenne Muscular Dystrophy (DMD)

$1,318.00

This Market Spotlight report covers the Duchenne muscular dystrophy market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

May 22, 2020

Find out more

Market Spotlight: Obesity

$1,318.00

This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

May 22, 2020

Find out more

Market Spotlight: Renal Disease

$1,318.00

This Market Spotlight report covers the renal disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

May 22, 2020

Find out more

Disease Analysis: Dyslipidemia

Dyslipidemia refers to any increase or decrease in lipid levels from defined normal parameters, with physicians particularly focusing on the treatment of elevated LDL-C due to the well-established link between excessively elevated LDL-C and atherosclerosis. As such, LDL-C is a major modifiable risk factor for cardiovascular disease, one of the world’s leading causes of morbidity and mortality, though differences in LDL particle morphology can also play a role

May 13, 2020

Find out more

Disease Analysis: Osteoporosis

Osteoporosis is the most common metabolic bone disease, and is characterized by compromised bone strength which predisposes individuals to an increased risk of fracture. Bone strength itself is not directly measurable, but can be inferred from bone mass and quality, with bone mass being most commonly approximated by assessing bone mineral density (BMD). A person with a BMD measurement that falls within one standard deviation (SD) of the healthy reference (30-year-old male or female) is considered to have healthy bone mass and structure (T-score >-1).

May 8, 2020

Find out more

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Reimbursement

$599.00

This reimbursement interview with a US key opinion leader (KOL) provides insight into pricing strategies, pricing barriers, and potential reimbursement criteria for non-alcoholic steatohepatitis therapies.

May 20, 2019

Find out more

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – France

$599.00

This interview with a French key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies and future treatment rates for the different fibrosis stages of NASH.

May 20, 2019

Find out more

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US

$599.00

This interview with a US key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies, diagnostic tools, and future treatment rates for the different fibrosis stages of NASH. Key pipeline assets highlighted include Ocaliva, elafibranor, cenicriviroc, and firsocostat.

May 20, 2019

Find out more

Dyslipidemia Disease Analysis and Market and Forecast Analysis 2024

Dyslipidemia refers to any increase or decrease in lipid levels from defined normal parameters, with physicians particularly focusing on the treatment of elevated LDL-C due to the well-established link between excessively elevated LDL-C and atherosclerosis.

June 7, 2018

Find out more

Chronic Kidney Disease Market and Forecast Analysis to 2035

Chronic kidney disease is a progressive condition affecting over 10% of the world’s population, and is characterized by kidney damage and impaired kidney function.

April 11, 2018

Find out more

Chronic kidney disease

Chronic kidney disease (CKD) is a long-term condition characterized by declining kidney function

and kidney damage that affects over 10% of the world’s population.

December 13, 2016

Find out more